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Abstract
Obesity is a widespread crippling and life-shortening dis-
ease that can be defined as a pathologic accumulation of fat
reserves. In spite of its epidemic distribution, no fully effec-
tive treatments are available. The strategies used for the
treatment of obesity have relied mainly on the limitation of
energy intake or/and increasing energy expenditure. The
most widely used method to limit energy intake has been the
use of hypocaloric diets. Their effectivity is limited and fade
away rapidly with time. Nevertheless, the sound use of
hypocaloric diets is yet the mainstay of the fight against
overweight. Inhibition of the absorption of nutrients through
specific digestive enzyme inhibitors has been also used.
Bariatric surgery is now practically the only fairly effective
way to treat the morbidly obese. Conductist conditioning has
been used to maintain the obese as far as possible from
food, but the results are often poor. However, adequate ins-
truction of the obese on basic nutritional knowledge, and
nutritional reeducation are a tool not to be neglected. Exer-
cise is the easiest way to increase energy expenditure. but
this increase is only transient; in any case it potentiates the
slimming effects of dietary restriction. There are a growing
number of drugs used for the treatment of obesity, and more
are just being under study and development. The main tar-
get of these drugs is to diminish the cravings of appetite as
a way to help the obese to limit ingestion, but other drugs
tend to increase thermogenesis, easing the consumption of
fat reserves; often both effects add up. The most widely
studied drugs are serotonergic drugs acting on the brain
and adrenergic agents acting both on appetite and heat
production. Several hormones, metabolites and even poi-
sons have been postulated as antiobesity agents, but now
the most promising areas of study rely on hypothalamic con-
trol of appetite, thermogenesis and regulatory control of the
mass of fat, the latter achieved through signalling molecules
produced by the adipose tissue. Many avenues have been
Resum
L’obesitat és una malaltia molt estesa que Iimita I’activitat i
escurça Ia vida, i que es pot definir com un emmagatzema-
ment patològic de reserves de greix. Malgrat Ia difusió
epidèmica, no hi ha cap sistema plenament efectiu disponi-
ble per tractar-Ia. Les estratègies emprades per al tracta-
ment de I’obesitat s’han basat principalment en Ia Iimitació
de Ia ingesta i/o l’increment de Ia despesa energètica. EI
mètode més emprat per Iimitar Ia ingesta energètica ha es-
tat Ia utilització de dietes hipocalòriques, però l’efectivitat és
Iimitada i es perd ràpidament amb el temps. Malgrat això, Ia
utilització adequada de dietes hipocalòriques constitueix
encara el principal procediment en Ia Iluita contra el so-
brepès. També s’ha emprat el bloqueig de I’absorció de nu-
trients mitjançant Ia inhibició específica d’enzims digestius.
La cirurgia bariàtrica és ara pràcticament I’únic mètode
prou efectiu per tractar els obesos mòrbids. S’ha utilitzat el
condicionament conductista per mantenir els obesos allun-
yats del menjar, però els resultats són sovint poc satisfacto-
ris. No obstant això, Ia informació adequada que reben els
obesos sobre els principis elementals de Ia nutrició, així
com Ia reeducació nutricional són una eina que no s’ha de
deixar de costat. L’exercici és Ia forma més senzilla d’aug-
mentar Ia despesa energètica i, tot i que aquest increment
és sols transitori, potencia els efectes aprimadors de Ia res-
tricció dietètica. Hi ha un nombre considerable de fàrmacs
que han estat emprats per al tractament de I’obesitat i enca-
ra n’hi ha més que estan essent estudiats i desenvolupats.
EI principal objectiu d’aquests fàrmacs és disminuir Ia gana
a fi d’ajudar I’obès a reduir la quantitat de menjar, però al-
tres drogues tendeixen a incrementar Ia termogènesi, tot fa-
cilitant Ia utilització de Ies reserves grasses; sovint ambdós
efectes tenen lloc a l’hora. les drogues més àmpliament es-
tudiades són Ies serotoninèrgiques, que actuen sobre el
cervell, i els agents adrenèrgics que actuen sobre Ia gana i
Ia producció de calor. Diverses hormones, metabòlits i fins i
tot verins han estat postulats pee al tractament de I’obesitat,
però ara per ara Ies àrees d’estudi amb més possibilitats de
futur són Ies basades en el control hipotalàmic de Ia gana,
Ia termogènesi i el control regulador de Ia massa de greix
mitjançant molècules senyal produïdes pel propi teixit adipós.
S’han investigat moltes vies per trobar formes efectives per
tractar I’obesitat, però Ia major part dels esforços encara es-
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probed to try to find an effective way to treat obesity. Howev-
er, most of the efforts are yet focussed on the development
of partial solutions to the complex problem of obesity. Coor-
dinated effort of basic research, and the development of ef-
fective drugs together with adequate information of the pa-
tients and actualization of the knowledge of the health
personnel working in the field are needed to face the threat
of dangerous and uncontrollably spreading obesity
tan orientats a trobar solucions parcials al complex proble-
ma de l’obesitat.
L’esforç coordinat en recerca bàsica i el desenvolupa-
ment de fàrmacs efectius, junt amb una adequada informa-
ció als pacients i I’actualització dels coneixements del per-
sonal sanitari que treballa en aquest camp, són les
condicions essencials per poder fer front a aquesta malaltia
perillosa que s’estén d’una manera incontrolada: I’obesitat.
Obesity is one of the main health hazards afflicting our con-
temporary society. Its widespread occurrence and increas-
ing severity would undoubtedly qualify it as an epidemic [1],
if only its origins could be traced to a transmissible agent.
Obesity has for too long now been considered simply as a
case of an unbalanced energy budget, the emphasis being
placed on the intake [2]; the association between excessive
food intake and obesity having been established at a time
beyond historical memory and frequently in conjunction with
sinfulness, lack of control and a delight in earthly pleasures
[3, 4]. Unfortunately, most of these time-worn beliefs remain
alive and deeply ingrained in the minds of a large section of
our society, even in those of a sizeable part of the medical
establishment [5]. An awareness of the perils of obesity and
being overweight has been awakened by major medical ad-
vances in the treatment of many of the other scourges facing
humankind in the last century. However, the efforts devoted
to the treatment of obesity have not kept pace with our
knowledge of other diseases; furthermore, the assumption
that obesity is more a consequence of moral flaws or feeding
incontinence has given rise to an often complacent indiffer-
ence in the fruitless struggle of the obese to shed their sinful
blubber.
Attempts at the global treatment or prevention of obesity
have led to marked alterations in the diet of whole countries -
restricting the intake of carbohydrates, energy, fats, and oth-
er dietary components [6-8]. These large scale experiments
failed to achieve their goals and instead led to higher inci-
dences of obesity, disrupted dietary habits, and increases in
the pathologic fears of being overweight resulting in anorex-
ia and bulimia [9].
However, the ever-growing numbers of people afflicted
with weight problems and obesity [10, 11], the increasing
numbers of people fearful of becoming obese [12], the limit-
ed effects of anti-obesity therapy, and a better scientific
knowledge of the disease, mean that these beliefs are now
being called into question. Obesity is a disease [13] -a crip-
pling and life-shortening disease - that probably has no sin-
gle metabolic origin [14]. Our understanding of certain obe-
sity syndromes in rodents has persuaded a number of
researchers to look upon genetics as the source of human
obesity [15].
Obesity as a disease
Obesity can be defined as a pathologic accumulation of fat
reserves; the extent of lipid storage far outstrips what the
body would be able to use in an emergency, and so this
storage just adds weight, thereby limiting movement, over-
loading the respiratory and cardiovascular systems and
destabilising the homeostatic equilibrium of the body [16].
The medical definition of obesity, however, is somewhat
more difficult, since a considerable grey area extends be-
tween what is considered normal and being overweight
and also between this mild situation and a fully developed
obesity. In addition, the actual mass of fat is not as critical
as is its specific location in terms of the pathological effects
of this fat and its impact on the hormonal and metabolic en-
vironment. In fact, there are a number of grossly obese pa-
tients that show much less marked metabolic abnormalities
than others in whom fat accumulation is not severe but who
present concurrent pathologic traits. These include hyper-
tension, hypercholestrolemia, hypertriacylglycerolemia and
type 2 diabetes mellitus: the metabolic or X syndrome [17].
It is still unclear as to whether hormonal alterations (i.e. in
insulin and glucocorticoids) are an early consequence of
excessive fat accumulation, or whether the latter is a con-
sequence of the former. Given the wide diversity of obesi-
ties, there are probably many explanations of the etiology
of obesity. There is a considerable body of evidence, how-
ever, linking obesity and type 2 diabetes mellitus, which
suggests that alterations in insulin functionality and re-
sponses play a key role in the development and mainte-
nance of obesity; the almost universal existence of insulin
resistance in the obese points to this single metabolic alter-
ation as the most critical element in the etiopathogenics of
obesity [18, 19].
Figure 1 shows a simplified diagram of the system that
controls body weight. The hypothalamic control of food in-
take is modulated by signals from the intestine, the levels of
metabolites in the blood and by signals from other brain nu-
clei; these also control efferent signals through the sympa-
thetic nervous system that regulates fat mobilisation and
thermogenesis. Two other major elements complete the pic-
ture: insulin, the main endocrine agent enhancing the build-
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up of reserves, and ponderostat signals emanating from the
adipose tissue and informing the brain about the mass of fat
stores.
Since obesity is in itself evidence that the energy budget
has been altered, most efforts at treating it have been
aimed at its external manipulation: i.e. increasing energy
expenditure and decreasing energy availability. However,
the manifold system that controls the body energy budget
is able to maintain its homoeostatic integrity by withstand-
ing external manipulation and diminishing the impact of the
therapeutic measures used to diminish the mass of fat. The
body reacts in a similar way to starvation in times of famine
and limited food availability because of the use of thera-
peutic hypocaloric diets: in both cases the mass of fat re-
serves is protected by limiting energy expenditure [20],
mainly thermogenesis [21, 22], and by improving the over-
all efficiency of the system. This alone may explain why it is
so difficult to shed fat simply by dieting and the rapid re-
covery of weight once the energy intake limitations are lift-
ed [23].
Dietary treatment
Table 1 summarises the procedures available for the treat-
ment of obesity, and Tables 2-5 present in more detail the
pharmacological strategies developed to achieve this goal.
The energy balance can be shifted to reduce the mass of
stored energy either by diminishing energy intake, increas-
ing energy expenditure or by altering the overall settings of
energy homeostasis by adequately modulating metabolic
signals. The main avenue taken for obesity treatment has
been the limitation of energy intake. This could be achieved
by decreasing the amount of food eaten - either by decreas-
ing the availability of the nutrients contained in the food or by
decreasing appetite, i.e. the drive to get that food. The main
problem with decreasing food availability is the reactive en-
hancement of appetite pangs, which cause deep and con-
stant discomfort, regardless of the method adopted to pre-
vent access to food. Thus, the control of appetite seems a
safer way to limit food intake, thus preventing this food from
fuelling the overall energy budget.
The most widely used method to limit energy intake has
been the use of hypocaloric diets [24]. Their effectiveness
is limited and fades rapidly with time, but it may be suffi-
cient to correct a problem of excess weight if properly ap-
plied [24]. The earlier use of therapeutic fasting or zero-en-
ergy diets [25] proved to be fairly ineffective in the long run,
and potentially harmful for the patients; in any case, the or-
deal of nil energy intake and the dangers this represented
for the nitrogen balance did not justify the slow and limited
loss of fat, which, moreover, were often matched by similar
losses of lean body mass [26]. This problem was partially
corrected with very low calorie diets (VLCDs), which sup-
plied only limited energy (1-3 MJ/day) but provided enough
protein to counter the obligatory nitrogen losses [27, 28]. In
any case, a significant part of the protein is simply used as
a source of energy, which in the end results in negative ni-
trogen balances. This may limit the prolonged application
of VLCDs, and thus hamper their success on morbid obesi-
ty. After overcoming a number of problems related to the
quality of the protein used [29, 30], VLCDs remained a
widely used tool for the management of the obese, proba-
bly because of the scarcity of other proven therapeutic
tools [31].
Hyperproteic diets have been used to shed fat and to
build up muscle masses, often in combination with anabolic
steroids and extensive exercise, especially by body-
builders [32]. Diets exclusively composed of protein are not
adequate for humans, because of the heavy overload of ni-
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Figure 1. Main mechanisms controlling the mass of body fat reserves.
trogen waste, the relatively low amount of energy derived
from it and other, as yet, unascertainable reasons that make
them highly dangerous. People using them for a long time
tend to lose weight, but no hard data are available as to why
they are invariably discontinued. The use of amino acid mix-
tures as supplements has been postulated as a way to di-
minish body fat [33], but the mechanism has not been ex-
plored and the results are poor.
The use of hypocaloric diets, often without medical super-
vision, is widespread. This repeated use favoured the ap-
pearance of a number of fad diets, some of them extremely
dangerous [34]. Also, the half-hearted repetitive exposure to
hypocaloric diets often results in an adaptation to them. Re-
fractary obesity is virtually impossible to treat with dietary
measures, since the body adapts to periodic low-energy
availability exposure and effectively protects fat stores [35].
Nevertheless, the sound use of hypocaloric diets, complete
with enough carbohydrate protecting protein oxidation and
a variety of appetising meals, remains the mainstay of the
fight against excess weight [24]. The use of dissociated and
ketogenic diets do not result in greater fat loss than those
produced by most of the hypocaloric diets [36]. However,
the former are dangerous because of acidosis and the threat
to lean body mass [37], and they represent a constant over-
load on the hepatic function. Moreover, the ketone bodies
further lower thermogenesis [38], thus making it even more
difficult to imbalance the energy equilibrium to drain the fat
reserves.
The availability of acaloric foods or low-calorie food sub-
stitutes (Table 2), combined with the so-called «light» prod-
ucts, in which the energetic density is lower than in similar
foods, has brought upon us a culture of non-energy foods fu-
elled by considerable commercial interests. The main tar-
gets for these substitutes have been sugars, with the wide-
spread availability of artificial sweeteners [39] such as
saccharin, cyclamate, aspartame, acesulfame-K, etc. [40],
but also fat substitutes, such as olestra [41].
Another way to diminish the availability of nutrients is to
use nutrient absorption modifiers. These disturb or retard the
absorption of certain nutrients [42]. The use of high-fibre
foods or fibre preparations helps prolong the absorption of
glucose and other nutrients, thus limiting the insulin re-
sponse, but it also helps to limit cholesterol and the reab-
sorption of bile salts [43]. The use of these modifiers in the
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diminishing decreasing restrictive hypocaloric diets
energy intake energy intake
low calorie or acaloric foods
mechanical jaw wiring
barriers to intake
gastric balloon
gastroplastia
decreasing decreasing food surgical bypasses
nutrient availability absorption
drugs decreasing nutrient availability
dietary manipulation dissociated and ketogenic diets
hyperproteic diets
decreasing appetite psychologycal methods conductist conditioning
suggestion, autocontrol and magic
anorectic drugs
increasing energy exercise
expenditure
increasing exposure to cold
thermogenesis
thermogenic drugs
modulating energy diminishing adipose inhibition of adipocyte differentiation
homeostasis tissue mass
surgical removal lipectomy
liposuction
localized adipose tissue lysis
immunological targeting of adipose tissue
homones / drugs modulating energy homeostasis
Table 1. Systems for the treatment of obesity
treatment of obesity is fairly irrelevant, but they may be use-
ful in the improvement of diabetes and hypercholesterolemia
so often associated with obesity.
Complex carbohydrate and fats constitute the bulk of en-
ergy intake for most humans. To be absorbed and further
metabolized or incorporated in our body systems, they need
to be digested by specific hydrolases in our intestine. The in-
hibition of these processes, then, would prevent the assimi-
lation of their energy. This is the reason why digestive en-
zyme inhibitors have been developed to help limit the
extraction of energy from the foods. Inhibitors of disacchari-
dases, amylases and lipases have been developed and
tested [44], but only one example of a lipase inhibitor, orlis-
tat, is currently available for the treatment of overweight con-
ditions and mild obesity [45]. The chronic use of inhibitors,
however, should be considered essentially as a comple-
mentary measure accompanying hypocaloric dieting, since
they cannot act alone [46]. Dieting is necessary also be-
cause the undigested substrates (essentially starches) can
be easily used by the colonic flora, which may produce dis-
comfort and generate a number of short-chain fatty acids
that are assimilated and contribute to our energy budget.
The presence of undigested lipid in stool may also induce in-
testinal discomfort and incontinence, a reason why the ad-
ministration of this drug should be made in parallel to a diet
with limited fat content [47].
Surgical treatment
Jaw-wiring has been used to a limited extent to prevent pa-
tients from eating [48]; in addition to the obvious inconve-
niences of such a drastic procedure, the unlimited intake of
often highly hypercaloric fluids may easily circumvent the ef-
fectiveness of the device. The need for these heroic meth-
ods is inversely proportional to the commitment of the pa-
tient to limit food intake - no barrier could overcome the
ingenuity of a starving human being. The active and enthusi-
astic collaboration of the patient is essential for any restric-
tive measure to be effective.
The stretching of the stomach using inflatable balloons
also prevents food ingestion, but also quells the appetite to
some extent [49]. However, the contraptions are cumber-
some to install and to inflate and they cannot resist the high-
ly acidic gastric juice for a long time; these complications
and the danger of rupture practically rule out their use.
The surgical removal of part of the stomach effectively
limits the amount of food that can be eaten, but it is irre-
versible. The introduction of reversible gastroplastic manip-
ulations [50], a relatively simple procedure, is now practically
the only fairly effective way to treat the morbidly obese [51].
However, these surgical procedures often need to be com-
plemented by intestinal by-passes [50] and vagotomy. [52],
thus adding malabsorption to the restriction effects. Bariatric
surgery is, thus, a major procedure, which in addition to the
avatars of any surgical operation, offer no absolute guaran-
tee of success, since it may result in massive and continued
losses of weight or in just a limited amount of fat being shed
[53]. Bariatric surgery also calls for a considerable psycho-
logical preparation on the part of the patient and a fairly long
period of adaptation to life with small stomach capacity and
malabsorptive intestines [54, 55]. In spite of these obvious
drawbacks, however, extensive bariatric surgery remains for
many morbid obese the only option to some degree of im-
provement in their condition [51].
Psychological treatment
The corollary of the assumption that obesity is a direct con-
sequence of excessive food intake is that the obese remain
as such because they lack enough stamina and willpower to
distance themselves from food, but also that they need
much less food to maintain their heavy bulk. In any case if
they are obese it is because they ingest more energy than
needed and the rest becomes fat [2]. Psychological meth-
ods, especially conductist conditioning, have been used to
maintain the obese as far as possible from food [56]. The re-
sults are often poor. However, adequate instruction of the
obese concerning basic nutritional knowledge, and nutri-
tional re-education are tools that should not be neglected,
especially in the aftermath of a significant reduction in body
weight, since adequate food habits are needed to maintain
the low weight attained [57, 58]. Stress is a significant con-
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action, types examples references
hypocaloric and acaloric food substitutes acaloric sweeteners aspartame [128]
acaloric or low-calorie fat substitutes olestra [129]
nutrient absorption modifiers gastric emptying delayers chlorocitrate [130]
nutrient absorption delayers chitosan [43]
bulk effect glucomannan [131]
digestive enzyme inhibitors intestinal disaccharidase inhibitors — [132]
α-amylase inhibitors acarbose [133]
lipase inhibitors orlistat [134]
Table 2. Drugs used –and drug-developing trends– for the treatment of obesity: I - Drugs decreasing nutrient availability
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action, types examples references
adrenergic agents α1-adrenergic agonists phenylpropanolamine [135]
β-adrenergic agonists amphetamine [61]
NA release enhancers phentermine [62]
NA reuptake inhibitors mazindol [63]
serotonergic agents 5HT precursors tryptophan [136]
agents decreasing 5HT turnover buspirone [137]
5HT post-synaptic agonists serotonin [138]
5HT release enhancers and reuptake inhibitors dexfenfluramine [66]
NA and 5HT release enhancers and reuptake inhibitors sibutramine [71]
intestinal peptides bombesin agonists bombesin [139]
CCK CCK protease inactivators butabindide [140]
CCK agonists CCK-8 [141]
glucagon-like agonists GLP-1 [76]
galanin antagonists — [75]
enterostatin agonists enterostatin [142]
dopaminergic agonists bromocriptine [143]
GABA-ergic agents GABA agonists — [144]
GABA transaminase inhibitors ethanolamine-sulphate [48]
histamine antagonists cimetidine [145]
opioid antagonists naloxone [146]
melatonin agonists malatonin [147]
cannabinoid antagonists — [148]
NO synthase inhibitors nitro-arginine [149]
cytokines TNFα [150]
metabolites glycerol [151]
hypothalamic CRH agonists CRH [152]
peptides
TRH agonists TRH [153]
CART agonists — [154]
MCH agonists — [155]
MC3 and MC4 receptor agonists — [156]
AGRP antagonists — [157]
nerve growth factor antagonists — [158]
NPY antagonists — [159]
anti-orexin compounds — [160
Table 3. Drugs used –and drug-developing trends– for the treatment of obesity: II - Anorectic agents
NA = noradrenaline; 5HT = serotonin; CCK = cholecystokinin; GABA = y-aminobutyrate; NO = nitrogen oxide; CRH = corticotropin rereasing hormone;
TRH = thyrotropin releasing hormone; CART = cocaine and amphetamine-related transcript; MCH = melanin-concentrating hormone; MC = melanocortin;
AGRP = Agouti-related peptide; NPY = neuropeptide Y; TNFα = tumour necrosis factor α; GLP-1 = glucagon-like peptide 1.
tributor to the development and maintenance of obesity [59],
and changes in daily habits, removal of stressful influences,
especially the morbid fear of becoming obese, may con-
tribute to check – albeit not to reduce – obesity.
Some of the bizarre treatments used for the treatment of
the obese are effective on a limited number of individuals
because of unknown mechanisms. However, where some
see magic we must interpret them as powerful cortical influ-
ences which we would very much like to understand and ex-
tend.
Appetite control: anorectic drugs
The obvious way to control food intake is to diminish the
cravings for food as a way to help the obese to limit inges-
tion, ensuring that the process is as painless as possible. In
the absence of hunger pangs not even the obese feel the
urge to eat. The control of the appetite has thus been a key
objective in drug development and today concentrates most
of the efforts for the development of anti-obesity drugs [60].
Table 3 shows a list of the types of drugs available and the
trends now being followed for the pharmacological control of
appetite.
The earlier drugs used for appetite control were ampheta-
mines [61], but soon their massive secondary (adrenergic)
effects, dependence and waning anorectic effect demon-
strated their scant efficiency as antiobesity drugs. Other
adrenergic agents have been developed and used [62, 63],
but in general their effects are limited and they are not ade-
quate for the treatment of obesity; common practice rele-
gates them to the treatment of limited overweight conditions
and then in combination with other therapeutic measures.
Serotonergic agents were initially developed as antide-
pressants; in some cases, as in the well known fluoxetine [64],
loss of appetite and diminution of body weight were a com-
mon occurrence, which prompted first the use of fluoxetine
[65] and later the development of a series of compounds that
helped control moderate obesity and overweight conditions,
often in combination with hypocaloric diets. Fenfluramine and
its active component, dexfenfluramine, were widely used for
several years [66]. The combination of fenfluramine and
phentermine [67], an adrenergic drug [62], resulted in signifi-
cant weight losses, but also produced dangerous side-ef-
fects that resulted in the removal of fenfluramine and dexfen-
fluramine from the market [68]. Sibutramine is the only
serotonergic drug available for the treatment of moderate
obesity [69, 70]. Its effects have been thoroughly tested, in-
ducing moderate weight losses in susceptible patients when
taken in combination with hypocaloric diets [71]. Long-term
treatment results in a significant improvement in obese pa-
tients [72]. This, and the limited availability of other more pow-
erful drugs makes sibutramine the choice drug for combined
diet-exercise and the pharmacological approach to the treat-
ment of moderate obesity [73].
The complex signalling pathways between the intestine
and the brain constitute another important research area for
the development of antiobesity drugs. Cholecystokinin
(CCK) has been the main target for these studies [74], but
other intestinal peptides, such as bombesin, galanin and
glucagon are currently being studied – essentially using ani-
mal models – in order to develop anorectic drugs [75, 76].
However, most of the efforts devoted to the development
of anorectic drugs are centred on the hypothalamus, where
the control over the appetite resides [77]. Both adrenergic
and serotonergic anorectic drugs act on the hypothalamus;
the ample variety of neurotransmitters involved in the control
of appetite is indicative of the extreme complexity of the
mechanisms involved [78]. The number of peptides known
to act on appetite control grows constantly, and with it the
expectations of new pathways for which drugs can be devel-
oped also keep widening [60]. Nevertheless, the sheer com-
plexity of the pathways involved, the size of the target, the la-
bile nature of peptides and the blood-brain barrier pose
huge obstacles to such developments. Furthermore, the
compensating nature of the systems controlling the mass of
body fat suggest that in any case anorectics may play only a
partial role in treating obesity, since simply by acting on
complementary systems (i.e. appetite and thermogenesis)
uncompensated fat losses may occur in the long run.
Treatment through increased energy expenditure
Exercise is the easiest way to increase energy expenditure,
but the increase is only transient - limited to the duration of
exercise. In addition, during exercise, thermogenesis is in-
hibited in order to prevent excessive use of the energy avail-
able and to facilitate the elimination of the heat evolved dur-
ing muscular action [79]. Thus, the effectiveness of exercise
as a tool in the treatment of obesity is a direct consequence
of its duration, and this is related to its intensity and the onset
of fatigue. Most obese show fatigue soon after beginning
even mild exercise, which further limits the eventual energy
expending effects of exercise. Moreover, the increase in res-
piratory and cardiovascular activity caused by exercise
among the obese are more marked than in individuals with
normal weight, which enhances the risk [80]. The use of
moderate exercise practised in a constant manner, howev-
er, in combination with hypocaloric diets helps prevent the
decrease in basal energy expenditure elicited by low energy
intake [21]. The combination of physical activity and low en-
ergy intake, thus, is the method of choice for the treatment of
moderate obesity and overweight conditions when this exer-
cise is feasible and well tolerated [81].
Other systems to increase energy expenditure include
exposure to the cold, since low temperatures are counter-
acted by parallel increases in thermogenesis [82]. However,
this is an impractical procedure that is most uncomfortable
and prone to develop complications, such as respiratory ail-
ments. These drawbacks prevent the actual use of cold ex-
posure for treatment of obesity. But thermogenesis has a
clear appeal for the pharmacological treatment of obesity:
any drug eliciting thermogenesis may help unbalance the
energy budget drawing reserves that end up simply as heat.
This has spurred considerable research (Table 4), based
especially on the uniqueness of brown adipose tissue as a
key thermogenic organ in rodents [83], and the finding of un-
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coupling protein (UCP-1) and its mechanism of action [84,
85]. The presence of atypical β-adrenergic receptors in this
tissue (β3-adrenoceptors) [86] prompted the active search
for specific agonists [87], which were expected to promote
thermogenesis without unwanted general adrenergic stimu-
lation [88]. Unfortunately, some species-specific differences
between murine and human receptors [89], and the counter-
acting effects of glucocorticoids [90] limited the effective-
ness of these drugs. In spite of magnificent perspectives
and a major effort by many pharmaceutical companies,
none of the β3 have yet been commercialised.
Direct elimination of adipose tissue
The direct action on adipose tissue is a fairly expedient way
to dispose of the problem – at least for a time. Several strate-
gies have been developed to achieve this goal, the most ob-
vious is the surgical removal of tissue, a huge task because
of the wide distribution of adipose tissue masses below the
skin and the location of visceral fat around and between key
splanchnic organs, muscles, vases and nerves. Extirpation
of a sizeable amount of fat through surgical means may re-
quire extensive and complex surgical procedures whose
risks are not justified. However, the excision of masses of
readily accessible fat –lipotomy– is used sometimes to ease
the burden of the obese, though more often for aesthetic
reasons; in any case it may significantly affect the body in
other ways [91]. Liposuction also removes fat, but its appli-
cations are also more common in plastic surgery than in the
treatment of obesity [92], since the mass of adipose tissue
removed is usually small. Massive liposuctions [93], elimi-
nating significant amounts of fat have seldom been used be-
cause of the painful and complicated recovery process.
Local treatment of adipose tissue masses with the injec-
tion of hormones and other lipolytic agents, as well as other
localised manipulations of subcutaneous fat depots are ex-
tensively used to shape the body for cosmetic purposes, but
their overall effect on adipose tissue mass is negligible. In
fact, the extensive use of thyroid hormone analogues in local
applications may unbalance the hormonal equilibrium and
induce reactive obesity [94], a reason why these localised
hormonal treatments should be ruled out.
The drastic elimination of adipose tissue using the im-
munological system is a possibility that has been explored
repeatedly by researchers [95], using anti-adipocyte anti-
bodies to wipe out adipose tissue [96]. These procedures,
however, entail considerable risks derived from the speci-
ficity of the antibodies and also because if successful, the
total elimination of adipose tissue would seriously hamper
the regulation of the energy budget, since the adipocyte is
not a mere store of fat reserves [97] but a source of hor-
mones: leptin, estrone and other regulatory components
[98].
Modification of energy control
The external modification of energy-transfer and utilization
mechanisms might also increase overall inefficiency, dis-
rupting the energy equilibrium and drawing energy from the
fat stores (Table 5). The most effective uncouplers are meta-
bolic poisons, in which therapeutic levels are extremely
close to those that produce dangerous side-effects [99].
These uncouplers are generally unsafe and not-discriminat-
ing, and their use may be seriously detrimental to the pa-
tient’s health, even resulting in death. More specific target-
ing, however, such as the inhibition of fatty acid synthesis
may constitute a viable mechanism to help prevent fat accu-
mulation [100]. Carnitine is extensively used as a food sup-
plement because it is often thought – without any hard data
though to support this belief – that a high availability of this
compound may help oxidize fats [101]. Other compounds
that tend to «enhance metabolism», such as amino acid
mixtures, have been suggested as alternatives for achieving
these goals, though here again, often without any sound ex-
perimental data to support their use.
Manipulation of energy control by either controlling intake
or increasing expenditure needs to take into account both
the counteracting modulation of the opposite mechanism
and the overall hampering effect of glucocorticoids [102-
105]. The best way to overcome these drawbacks is pre-
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action, types examples references
adrenergic agonists α1-adrenergic antagonists — [161]
α/β-adrenergic receptor blockers arotinolol [162]
β-adrenergic agonists ephedrine [163]
β3-adrenergic agonists — [164]
phosphodiesterase inhibitors amrinone [165]
BAT NA reuptake inhibitors and NA level enhancers ciclazandol [166]
calcium antagonists benidipine [167]
GABA agonists GABA [168]
respiratory chain / ATP synthesis uncouplers — [169]
Table 4. Drugs used –and drug-developing trends– for the treatment of obesity: III - Thermogenic drugs
cisely to target the center that modulates both legs of the
system, by affecting the ponderostat setting, and by allow-
ing those mechanisms that we have been trying to rein in to
work without external interference and in the required lipolyt-
ic direction. Since in obesity insulin resistance is perhaps
the main metabolic trait [18, 19], any improvement in this
condition by means of antidiabetic drugs may help restore
an adequate insulin homeostasis [106, 107].
Other hormones have been used to treat obesity: thyroid
hormones have been extensively used in the past [108], and
remain a significant component in unproven concoctions
prescribed by charlatans to their unsuspecting patients
[109]. Thyroid hormones do induce significant losses of
body weight [110] but may induce alterations in thyroid op-
eration. The availability of recombinant growth hormone led
to its being used in the treatment of obesity [111], and in
spite of limited success, research continues to develop GH-
related compounds that might be useful in the treatment of
obesity [112].
Androgens are not useful as anti-obesity drugs, but they
do reshape the distribution of fat and increase muscle mass
[113]. Massive doses of dehydroepiandrosterone (DHEA), a
mild androgen, induce slimming in rats with no ill-effects
[114], however, lower-dose applications to humans had no
significant effects on body weight [115]. Nevertheless,
DHEA tends to diminish the fat mass and to increase body
protein [116], and is extensively used as a food supplement.
Probably the main beneficial effect of DHEA is derived from
its antiglucocorticoid function [117], thus limiting the fat-pro-
moting actions of cortisol. Estrogens also tend to decrease
body weight by enhancing thermogenesis [118], but the ef-
fects are limited and overshadowed by their estrogenic ac-
tion.
Leptin is produced by the adipocyte [119], as is oleoyl-
estrone, in proportion to its mass [120, 121]. Leptin has been
postulated as a ponderostat signal [119], but hyperleptine-
mia of obese humans [120] precludes its use as an anti-obe-
sity drug, since the problem does not seem to lie in the avail-
ability of the protein but rather in how its signal reaches the
hypothalamic nuclei [122]. Oleoyl-estrone has also been
postulated as a ponderostat signal [123]; its administration
to rats reduces the mass of fat without affecting body protein
[124, 125]. In spite of the considerable amount of research
conducted to date on these putative ponderostat signals
[126, 127], further research has to be undertaken before this
promise can be turned into effective antiobesity drugs.
This overview of the treatment of obesity shows that many
avenues have been explored in an effort to find an effective
means of treatment. However, time-honoured concepts and
ideas endure and most of these efforts still focus on the de-
velopment of partial solutions to the complex problem of
obesity. More basic research and greater insights into obe-
sity are needed, if we are going to be able to tackle this ever
increasing problem in the next few years. A coordinated ef-
fort in the development of powerful, yet harmless, drugs is
needed together with the gathering of adequate information
about patients, while at the same time ensuring that the
health personnel working in this field are kept up to date in
their understanding of obesity; but most importantly, the real
threat of obesity as a dangerous illness that is spreading
without control must be clearly accepted and resoundingly
denounced.
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action, types examples references
hormones insulin action antidiabetic agents amylin [107]
modulators
insulin function enhancers chromium picolinate [170]
phosphotyrosine phosphatase inhibitors — [106]
growth hormone agonists growth hormone [111]
thyroid hormone agonists thyroxin [108]
antiglucocorticoids DHEA [116]
androgen agonists testosterone [113]
estrogen agonists β-estradiol [118]
oleoyl-estrone agonists oleoyl-estrone [125]
leptin agonists leptin [171]
metabolic controllers respiratory chain blockers dinitrophenol [99]
fatty acid synthesis inhibitors — [100]
mitochondrial fatty acid transport enhancer carnitine [101]
Table 5. Drugs used –and drug-developing trends– for the treatment of obesity: IV - Hormones and drugs modulating energy homeostasis ac-
tion, types
DHEA = dehydroepiandrosterone
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